Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazax in seasonal grass pollen induced rhinoconjunctivitis
NCT00421655Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2006
- Primary completion
- Aug 2007
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Grazax with Placebo (2 arms). Primary endpoint: Recording of allergy symptoms. Started Dec 2006; status: completed.
02
Drugs
grass-pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00421655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421655.